Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)

被引：0
|
作者：
Maubec, E. [1 ]
Boubaya, M. [2 ]
Deschamps, L. [3 ]
Beylot-Barry, M. [4 ]
Petrow, P. [5 ]
Scheer-Senyarich, I. [1 ]
Basset-Seguin, N. [6 ]
Marqueste, C. Gaudy [7 ]
Quereux, G. [8 ]
Bloch-Queyrat, C. [9 ]
Leccia, M-T. [10 ]
Stefan, A. [11 ]
Saiag, P. [12 ]
Grange, F. [13 ]
Meyer, N. [14 ]
Rat, S. Dalac [15 ]
Alloux, C. [16 ]
Lopez, I. [17 ]
Tibi, A. [16 ]
Levy, V. [18 ]
机构：
[1] Hop Avicenne, AP HP, Dermatol Dept, Bobigny, France
[2] Hop Avicenne, AP HP, Unite Rech Clin, Bobigny, France
[3] Hop Bichat Claude Bernard, APHP, Pathol, Paris, France
[4] CHU Bordeaux, Dermatol Dept, Hop St Andre, Bordeaux, France
[5] Polyclin St Come, Radiol, Compiegne, France
[6] Hop St Louis, AP HP, Paris, France
[7] CHU La Timone Enfants, AP HM, Dermatol Dept, Marseille, France
[8] CHU Nantes Hotel Dieu, Dermatol, Nantes, France
[9] Hop Avicenne, AP HP, Res Clin Unit, Bobigny, France
[10] CHU Grenoble Alpes, Dermatol, Site Nord La Tronche, La Tronche, France
[11] CHU Caen, Dermatol, Hop Cote Nacre, Caen, France
[12] Hop Ambroise Pare, AP HP, Dermatol & Oncol Dept, Boulogne, France
[13] Ctr Hosp Valence, Dermatol, Valence, France
[14] Ctr Hosp Univ Toulouse, Dermatol, Hop Larrey, Toulouse, France
[15] CHU Dijon, Dermatol, Dijon, France
[16] APHP, Pharm, Agence Gen Equipements & Prod Sante, Paris, France
[17] Polyclin St Come Assoc Cabinet Radiol & Imagerie, Radiol, Compiegne, France
[18] Hop Avicenne, Clin Res, Bobigny, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1139P
引用
收藏
页码：S682 / S683
页数：2
相关论文
共 50 条
  • [41] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [42] Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer:: a phase II study
    Feliu, J
    Salud, A
    Escudero, P
    Lòpez-Gómez, L
    Pericay, C
    Castañón, C
    de Tejada, MRL
    Rodríguez-García, JM
    Martínez, MP
    Martín, MS
    Sánchez, JJ
    Barón, MG
    BRITISH JOURNAL OF CANCER, 2004, 90 (08) : 1502 - 1507
  • [43] Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer
    Saad, ED
    Kraut, EH
    Hoff, PM
    Moore, DF
    Jones, D
    Pazdur, R
    Abbruzzese, JL
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05): : 451 - 453
  • [44] Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
    J Feliu
    A Salud
    P Escudero
    L López-Gómez
    C Pericay
    C Castañón
    M R López de Tejada
    J M Rodríguez-García
    M P Martínez
    M Sanz Martín
    J J Sánchez
    M González Barón
    British Journal of Cancer, 2004, 90 : 1502 - 1507
  • [45] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [46] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
  • [47] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [48] Sequential treatment with doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II GEICAM study
    Alba, E
    Antón, A
    Ribelles, N
    Pérez-Carrión, R
    López-Vega, J
    Llanos, M
    Pelegri, A
    Florián, J
    Menéndez, M
    Godés, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S66 - S66
  • [49] PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
    Ishak, W. Binti Wan
    Cheong, S.
    Nor, I. Muhamad
    Selvam, B.
    Ho, G.
    Tan, C.
    Wong, Y.
    Kue, P.
    Wai, A.
    Yahya, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1386 - S1386
  • [50] Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Nicholas J. Robert
    Paul R. Conkling
    Mark A. O’Rourke
    Paul R. Kuefler
    Kristi J. McIntyre
    Feng Zhan
    Lina Asmar
    Yanping Wang
    Oluwatoyin O. Shonukan
    Joyce A. O’Shaughnessy
    Breast Cancer Research and Treatment, 2011, 126 : 101 - 108
12345